Actualités, ressources, mises à jour
Une plateforme scientifique pour vous tenir informés de nos dernières recherches et de l'actualité de notre entreprise.
InnoSer et OrganoTherapeutics vont proposer des organoïdes du mésencéphale
InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...
Partenariat stratégique entre InnoSer et TheraIndx
InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...
InnoSer se dote de nouvelles installations de culture cellulaire
InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...
Subvention Eurostars pour MINDMAP
53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat...
Un bond vers l'avenir : développement d'une plateforme de criblage de médicaments PDXO
InnoSer NV, a young and innovative Belgium based Contract Research Organization (CRO) has received an over € 1.6 million grant from the Flemish VLAIO. This development grant is awarded to set up a PDXO screening platform in partnership with Vrije...
info@innoserlaboratories.com
Liens rapides